Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.

AZ's Imfinzi on target in small cell lung cancer, sets up Ro...

AstraZeneca’s Imfinzi cancer immunotherapy has hit the mark in a phase 3 trial in extensive-stage small cell lung cancer, setting up a potential rivalry with Roche’s PD-L1 class drug Tecent

Gilead joins protein degradation drive with Nurix deal

Daiichi waits on FDA as AML drug quizartinib approved in Jap...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.

Bayer's regorafenib kicks off brain cancer platform trial

Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.

AZ sees triple approval in Japan for cancer and COPD drugs

AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr